Revance Therapeutics | Driftskostnader

Operating Expenses Endring Dato
ALKERMES USD 337.09M 41.11M 2023-09
Eli Lilly USD 6.97B 2.08B 2023-12
Neurocrine Biosciences USD 357.6M 21.5M 2023-09
Pacira USD 148.08M 1.87M 2023-12
Supernus Pharmaceuticals USD 165.31M 19.57M 2023-12



Revance Therapeutics Driftskostnader - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Apr 2024.